Send us Feedback

Enzon Pharmaceuticals (ENZN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ENZN » Topics » PART II OTHER INFORMATION

This excerpt taken from the ENZN 10-Q filed Nov 2, 2006.

PART II OTHER INFORMATION

    Item 6. Exhibits

(a) Exhibits required by Item 601 of Regulation S-K.

Exhibit
Number		 Description   Reference
No.
 
3(i) Amended and Restated Certificate of Incorporation (Previously filed as an exhibit to the Company’s Current Report on Form 8-K filed May 19, 2006 and incorporated herein by reference thereto.)    
3(ii) Amended and Restated By-laws (Previously filed as an exhibit to the Company’s Form 10-Q filed August 3, 2006 and incorporated herein by reference thereto.)    
4.1 Rights Agreement dated May 17, 2002 between the Company and Continental Stock Transfer Trust Company, as rights agent (Previously filed as an exhibit to the Company’s Form 8-A12G (File No. 000-12957) filed with the Commission on May 22, 2002 and incorporated herein by reference thereto.)    
4.2 First Amendment to the Rights Agreement, dated as of February 19, 2003 between the Company and Continental Stock Transfer & Trust Company, as rights agent (Previously filed as an exhibit to the Company’s Form 8-A12G/A (File No. 000-12957) filed with the Commission on February 20, 2003 and incorporated herein by reference thereto.)    
4.3 Indenture, dated May 23, 2006, between Enzon Pharmaceuticals, Inc. and Wilmington Trust Company (Previously filed as an exhibit to the Company’s Current Report on Form 8-K filed May 25, 2006 and incorporated herein by reference thereto.)    
10.1 Executive Deferred Compensation Plan (2006 Restatement) (Previously filed as an exhibit to the Company’s Form 10-Q filed August 3, 2006 and incorporated herein by reference thereto.)    
10.2 Registration Rights Agreement, dated May 23, 2006, between Enzon Pharmaceuticals, Inc. and Goldman, Sachs & Co. (Previously filed as an exhibit to the Company’s Current Report on Form 8-K filed May 25, 2006 and incorporated herein by reference thereto.)    
10.3 2001 Incentive Stock Plan, as amended and restated, of Enzon Pharmaceuticals, Inc. (Previously filed as an exhibit to the Company’s Current Report on Form 8-K filed May 19, 2006 and incorporated herein by reference thereto.)    
10.4 First Amendment of Lease – 685 Route 202/206, Bridgewater,
New Jersey		   *
10.5 Second Amendment to Lease – 685 Route 202/206, Bridgewater,
New Jersey		   *
10.6 Third Amendment to Lease – 685 Route 202/206, Bridgewater,
New Jersey		   *
31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   *
31.2 Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   *
32.1 Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   *
32.2 Certification of Principal Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   *
  *      Filed herewith.

32

Back to Contents

"PART II OTHER INFORMATION" elsewhere:

BioCryst Pharmaceuticals (BCRX)
Cadence Pharmaceuticals (CADX)
Cerus (CERS)
Exelixis (EXEL)
GTC Biotherapeutics (GTCB)
Endo Pharmaceuticals Solutions Inc. (IDEV)
InterMune (ITMN)
Biota Pharmaceuticals, Inc. (NABI)
NGEN, INC. (NGEN)
Neurobiological Technologies (NTII)
ARCA biopharma, Inc. (NUVO)
Repligen (RGEN)
Sangamo BioSciences (SGMO)
Sequenom (SQNM)
Savient Pharmaceuticals (SVNT)
Tercica (TRCA)
Targacept (TRGT)
SYNAGEVA BIOPHARMA CORP (TRMS)
Vanda Pharmaceuticals (VNDA)
XOMA (XOMA)
Gilead Sciences (GILD)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki